NR4A1 and ovarian carcinoma: The contribution of endocrine GPCRs, including reproductive hormone receptors (e.g., G protein-coupled estrogen receptor, follicle-stimulating hormone receptor, luteinizing hormone receptor), hormone receptors involved in gonadotropin release (e.g., kisspeptin receptor, gonadotropin-releasing hormone receptor), or other hormone receptors (endothelin receptors, angiotensin II type 1 receptor) to ovarian cancer progression was extensively reviewed (see [14]).